ZyVersa Therapeutics Announces a Publication in Frontiers in Medicine Showing Direct Inflammasome Activation in Children with Juvenile Idiopathic Arthritis Read more about ZyVersa Therapeutics Announces a Publication in Frontiers in Medicine Showing Direct Inflammasome Activation in Children with Juvenile Idiopathic Arthritis
ZyVersa Therapeutics Announces Changes to ZyVersa’s Board of Directors Read more about ZyVersa Therapeutics Announces Changes to ZyVersa’s Board of Directors
ZyVersa Therapeutics Announces Article Published in Metabolism Pointing to Glomerular Cholesterol Accumulation as Key Factor Exacerbating Renal Injury and Dysfunction in Diabetic Kidney Disease Read more about ZyVersa Therapeutics Announces Article Published in Metabolism Pointing to Glomerular Cholesterol Accumulation as Key Factor Exacerbating Renal Injury and Dysfunction in Diabetic Kidney Disease
ZyVersa Therapeutics Reports First Quarter 2023 Corporate and Financial Results Read more about ZyVersa Therapeutics Reports First Quarter 2023 Corporate and Financial Results
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in A.G.P.’s Virtual Healthcare Conference Read more about ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in A.G.P.’s Virtual Healthcare Conference
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention Read more about ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention
ZyVersa Therapeutics Announces a Publication in Hepatology Revealing That Alcohol-induced Extracellular ASC Specks Perpetuate Liver Inflammation and Damage in Alcoholic Hepatitis Read more about ZyVersa Therapeutics Announces a Publication in Hepatology Revealing That Alcohol-induced Extracellular ASC Specks Perpetuate Liver Inflammation and Damage in Alcoholic Hepatitis
ZyVersa Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering Read more about ZyVersa Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference Read more about ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference
ZyVersa Therapeutics, Inc. Announces Pricing of $11.0 Million Public Offering Read more about ZyVersa Therapeutics, Inc. Announces Pricing of $11.0 Million Public Offering
